Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model by Caroline Morin et al.
Morin et al. Arthritis Research & Therapy  (2015) 17:142 
DOI 10.1186/s13075-015-0653-yRESEARCH ARTICLE Open AccessEicosapentaenoic acid and docosapentaenoic
acid monoglycerides are more potent than
docosahexaenoic acid monoglyceride to
resolve inflammation in a rheumatoid arthritis
model
Caroline Morin1,2*, Pierre U Blier3 and Samuel Fortin1,3Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of the joints and bones.
Omega-3 (ω3) fatty acid supplementation has been associated with a decreased production of inflammatory cytokines
and eicosanoids involved in RA pathogenesis. The aim of this study was to determine the therapeutic potential of ω3
monoglyceride (MAG-ω3) compounds in an in vivo rat model of RA induced by Complete Freund’s Adjuvant (CFA).
Method: CFA rats were untreated or treated per os with three specific compounds, namely, MAG-docosahexaenoic acid
(MAG-DHA), MAG-eicosapentaenoic acid (MAG-EPA) and MAG-docosapentaenoic acid (MAG-DPA). Morphological and
histological analyses, as well as pro-inflammatory marker levels were determined following MAG-ω3 treatments.
Results: Morphological and histological analyses revealed that MAG-EPA and MAG-DPA exhibited strong activity in
reducing the progression and severity of arthritic disease in CFA rats. Following MAG-EPA and MAG-DPA treatments,
plasma levels of the pro-inflammatory cytokines; interleukin 17A (IL-17A), IL-1β, IL-6 and tumor necrosis factor α (TNFα)
were markedly lower when compared to CFA-untreated rats. Results also revealed a decreased activation of p38
mitogen-activated protein kinases (p38 MAPK) and nuclear factor-kappa B (NFκB) pathways correlated with a reduced
expression of TNFα, cyclooxygenase-2 (COX-2), matrix metalloproteinase-2 (MMP-2) and MMP-9 in paw homogenates
derived from MAG-EPA and MAG-DPA-treated rats. Of interest, the combined treatment of MAG-EPA and vitamin E
displayed an antagonistic effect on anti-inflammatory properties of MAG-EPA in CFA rats.
Conclusion: Altogether, the present data suggest that MAG-EPA, without vitamin E, represents a new potential
therapeutic strategy for resolving inflammation in arthritis.Introduction
The severity and disease progression of rheumatoid arth-
ritis (RA) are governed by multiple factors including im-
mune, genetic and environmental factors [1]. Joint lesions
show infiltration of several immune cells including acti-
vated T lymphocytes, macrophages and antibody-secreting
B lymphocytes into the synovium concomitant with a pro-
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nus, which leads to progressive destruction of cartilage and
bone [2]. This phenomenon is most likely due to cytokine
and eicosanoid-mediated induction of destructive enzymes
such as matrix metalloproteinases (MMPs) [4]. Synovial
fluid from patients with RA contains high levels of pro-
inflammatory cytokines including TNF-α, IL-1β, IL-6, IL-8,
IL-17A and granulocyte/macrophage colony stimulating
factor (GMCFS) [5, 6]. Furthermore, both local and sys-
temic levels of each cytokine are linked to disease severity
[7–9]. Immune cells involved in RA usually contain a high
proportion of the n-6 arachidonic acid (AA) and lowicle distributed under the terms of the Creative Commons Attribution License
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(PUFAs), with AA considered to be the major substrate for
synthesis of eicosanoids [3]. Eicosanoids produced by both
the cyclooxygenase (COX) and lipoxygenase (LOX) path-
ways are found in the synovial fluid of patients with active
RA [10]. For example, expression of COX-2 is increased in
the synovium of patients with RA and in joint tissues in
rat models of arthritis [10, 11]. Protaglandin E2 (PGE2)
and leukotriene B4 (LTB4), two eicosanoids respectively
produced by COX and LOX, display a number of pro-
inflammatory effects (including increasing vascular perme-
ability), enhance local blood flow, are potent chemotactic
agents for leukocytes, induce the release of lysosomal en-
zymes and enhance the release of reactive oxygen species
and cytokines such as TNF-α, IL-1β and IL-6 [4, 10]. They
also promote the production of destructive MMPs and
stimulate bone resorption [2].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are
currently used to decrease pain and inflammation in RA
patients [1, 12]. These agents exert their analgesic effects
by inhibiting COX. Treatment of RA with NSAIDs, while
improving symptoms, may lead to side effects such as
gastrointestinal (GI) toxicity, osteoporosis, diabetes melli-
tus, weight gain, increased blood pressure, increased risk
of heart failure and increased cardiovascular risk [3, 12].
As a result, these adverse effects have led to the restriction
of NSAID use for the treatment of RA.
The dietary ω-3 PUFAs eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), originating from fish oils,
are also considered to reduce pain and inflammation in
RA via the following mechanisms: ω-3 PUFAs competi-
tively inhibit the production of PGE2 and LTB4, which in
turn inhibit the activation of NFκB, and thus the release of
inflammatory cytokines such as IL-1β and TNFα [13].
Moreover, ω-3 PUFA-derived mediators, including E-
series resolvins (Rvs) such as RvE1 from EPA as well as
D-series Rvs and protectin D1 from DHA, exert potent
anti-inflammatory, inflammation resolving and immuno-
modulatory actions both in vitro and in vivo [14]. The ratio
of ω6/ω3 PUFAs is important in RA pathogenesis with each
of these acids differing in their efficacy. For example, EPA >
DHA is effective against inflammation-induced arthritic
markers in animal studies [15]. Studies using fish oil in
patients with RA report decreased IL-1 production by
monocytes [16] and decreased circulating concentrations of
IL-1β, TNFα and soluble receptor activator of NFκB ligand
[17, 18]. Moreover, clinical trials with ω3 PUFA supplemen-
tation have reported an improvement in the number of ten-
der joints on physical examination, the Ritchie articular
index, morning stiffness and decreased NSAID require-
ments [3, 19–25]. A meta-analysis of randomized con-
trolled trials confirmed that ω-3 PUFA supplementation
improves clinical symptoms of RA [26]. Moreover, a recent
clinical trial demonstrated that fish oil used as adjunctivetherapy in the context of modern treat-to-target drug treat-
ment for recent onset RA both increased rates of remission
and decreased drug use [27]. However, the conclusions of
several clinical studies have shown consistent evidence for a
modest clinical efficacy of marine ω3 PUFAs in RA.
In light of the above, EPA, DHA and docosapentaenoic
acid (DPA) sn1-monoacylglycerides, namely eicosapenta-
enoic acid monoglyceride (MAG-EPA), docosahexaenoic
acid monoglyceride (MAG-DHA) and docosapentaenoic
acid monoglyceride (MAG-DPA), were synthesized in order
to: 1) evaluate their effects on arthritic disease severity in a
complete Freund’s adjuvant (CFA)-induced rat model, and
2) to monitor inflammatory arthritis activity using bio-
chemical and histological analyses. Indeed, MAG-ω3 com-
pounds are well-absorbed by the GI tract, are non-toxic,
and their metabolites are found in blood circulation and
tissues [28–31]. Specifically, we assessed the effects of
treatment with MAG-ω3 compounds on morphological,
clinical and histological features of arthritis disease. More-
over, the level of inflammatory markers (IL-17A, IL-1β,
IL-6, TNFα, COX-2), the activation of p38 mitogen-
activated protein kinase (MAPK) and NFκB pathways, as
well as the levels of MMP2 and MMP-9 were determined
following MAG-ω3 treatments. Results indicated that
MAG-EPA and MAG-DPA exert more potent anti-
inflammatory and pro-resolving effects than MAG-DHA
in a CFA model of arthritis, a finding consistent with the
inhibition of NFκB and p38MAPK pathways.
Materials and methods
Synthesis of ω3 PUFA monoacylglycerides
MAG-DHA, MAG-EPA and MAG-DPA were synthesized
as previously described [28, 29, 32].
Animal model of arthritis
CFA was used to initiate induction of arthritis. Adult (10
weeks) female Lewis rats weighing 180 to 200 g were
obtained from Charles River Laboratories (Montreal, QC,
Canada). Rats were housed in our animal facilities in a
12:12-h light-dark cycle, at 22 ± 2 °C ambient temperature,
and maintained on normal rodent chow and tap water ad
libitum. Rats were acclimated 7 days before starting the
experiments. All studies involving animals were approved
by the institutional animal care committee of the Univer-
sité du Québec à Rimouski (Protocol: # CPA-53-13-120).
The rats were injected intradermally with 0.2 ml of CFA
(Chondrex, Inc. Redmond, WA, USA) at the base of the
tail. To increase the severity of arthritis, a booster injec-
tion with 0.1 ml of CFA was administered in the same
manner on day 5. Measurements were obtained from both
the inflamed and non-inflamed hind paws. The hind paw
thickness (mm) was measured using a digital caliper. The
severity of arthritis in the rats was assessed daily and scor-
ing was attributed semiquantitatively (0: normal, with no
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of one joint; 2: moderate, redness and swelling in two joints;
3: redness and swelling in more than two joints; 4: severe
arthritis in multiple joints including the entire paw).
Rats were randomly assigned into five groups: 1) control;
2) CFA; 3) CFA+ MAG-EPA-treated 4) CFA + MAG-
DPA-treated, and 5) CFA + MAG-DHA-treated. MAG-ω3
compounds (318 mg/kg) were given orally directly to the
back of the mouth with a pipette tip. MAG-ω3 treatments
were administrated daily. The oral dose of 318 mg/kg was
chosen according to Health Canada Draft Guidelines to
obtain a human equivalent dose of 3.0 g/day (60 % of the
maximum daily dose allowed by Health Canada) [33].
Oral administration of MAG-ω3 compounds were initi-
ated 15 days after the initial CFA injection and continued
until study termination (day 22). Macroscopic signs of se-
vere arthritis at 20 days included swelling, redness, deform-
ity and ankyloses in the hind paw and ankle joints. At the
end of the experiment, all five groups of rats were eutha-
nized by a lethal dose of pentobarbital and blood and tissue
samples were collected for further analyses (Scheme 1).
Additional experiments were performed to determine
the effect of vitamin E and MAG-EPA treatments in CFA
rats. MAG-EPA (318 mg/kg) and vitamin E (53 mg/kg)
was given as a single dose orally directly to the back of the
mouth with a pipette tip. Combined treatment was admin-
istrated daily 15 days following CFA injection after which
its effects on hind paw thickness, COX-2 expression levels
and pro-inflammatory cytokine profiles were evaluated.
Western blot analysis
Western blots using specific antibodies against the phos-
phorylated forms of p65 NFκB (P-p65NFκB), p38MAPK
(P-p38MAPK), as well as NFκB, p38 MAPK, COX2,
TNFα, MMP-2 and MMP-9 and β-actin proteins were
performed on hind paw homogenate fractions derived
from control and CFA rats, either untreated or treated
with MAG-EPA, MAG-DPA or MAG-DHA, as previously
described. All antibodies used were obtained from New
England BioLabs, Pickering, ON, Canada: 1 μg/ml of the
selected specific antibody in TBS-T + 5 % BSA wereScheme 1 Experimental design and schedule of treatment in rat model ofincubated overnight at 4 °C. Immunostains of the blots
were digitized and analyzed with Lab-Image software 2.7.
Histological analysis
Rat tissues were fixed in 10 % buffered formalin and
paraffin-embedded after which thin sections (3-μm thick)
were stained with hematoxylin-eosin according to standard
protocols [29]. Images were acquired with a Hamamatsu
ORCA-ER digital camera attached to a Nikon Eclipse TE-
2000 inverted microscope (Nikon-Canada, Mississauga,
ON, Canada). Images were obtained (objective 20×)
from hind paw sections derived from control, CFA, CFA +
MAG-DHA-, CFA + MAG-EPA- and CFA + MAG-DPA-
treated rats.
ELISA assays
Measurements of key pro-inflammatory cytokines includ-
ing IL-17A, IL-1β, IL-6 and TNFα were measured by spe-
cific ELISA on day 22 in plasma derived from control,
CFA, CFA + MAG-DHA-, CFA + MAG-EPA- and CFA +
MAG-DPA-treated rats, according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN, USA).
Data analysis and statistics
Results are expressed as means ± standard error of the
mean (SEM), with n indicating the number of experi-
ments. Statistical analyses were performed using Sigma
Plot 11 and SPSS 14.0 (SPSS-Science, Chicago, IL, USA)
using one-way analysis of variance (ANOVA) followed
by Dunnett’s post-hoc test. Differences were considered
statistically significant when P was <0.05.
Results
Effects of MAG-ω3 on arthritis severity
The anti-inflammatory activity of MAG-DHA, MAG-
EPA and MAG-DPA was assessed in a rat CFA model, a
widely-used model for human RA. Figure 1a illustrates
hind paw diameter measurements from control, CFA,
CFA + MAG-DHA-treated, CFA + MAG-EPA-treated
and CFA + MAG-DPA-treated rats. Results indicate that
18 days following initial CFA injection, hind paw thick-
ness of CFA-untreated rats was significantly increasedrheumatoid arthritis
Fig. 1 Effects of MAG-ω3 compounds on arthritis severity. a Hind paw thickness (mm) as a function of time (days) was measured in control and
in complete Freund’s adjuvant (CFA) rats, either untreated or treated with docosahexaenoic acid monoglyceride (MAG-DHA), eicosapentaenoic
acid monoglyceride (MAG-EPA) or docosapentaenoic acid monoglyceride (MAG-DPA) (318 mg/kg). MAG-ω3 compounds were administered at
15 days post-CFA injection onward. Six control and six CFA rats were sacrificed on day 22 at the same time as CFA + MAG-ω3-treated rats for
pro-inflammatory marker analyses, whereas six controls and six CFA rats were sacrificed on day 29 to evaluate the progression of arthritis over
time. Results represent the mean ± standard error of the mean (n = 6 per group for MAG-ω3-treated animals and n = 12 for control and CFA
rats). b Clinical arthritis score as a function of time was determined in untreated and treated CFA rats (n = 12 for untreated and n = 6 for treated
conditions). c Macroscopic images of hind paw derived from control, CFA and CFA+MAG-EPA-treated rats. Hematoxylin-eosin staining of hind
paw thin sections derived from Control (d): CFA (e) and CFA + MAG-EPA-treated animals (f). Bar = 50 μm
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0.01 mm, Fig. 1a). MAG-DHA treatment of CFA rats re-
sulted in a transient reduction in hind paw thickness
following the first and second treatment day, whereas on
day 18 to 22, hind paw thickness measurements in-
creased to reach the same level as that of CFA-untreated
rats (Fig. 1a). In contrast, treatment of CFA rats with
MAG-DPA and MAG-EPA resulted in a significantreduction in hind paw thickness when compared to un-
treated CFA rats (Fig. 1a). Moreover, data indicated that
MAG-EPA displayed a more potent effect on the reduc-
tion of hind paw swelling and redness on day 20 to 22
than MAG-DPA treatment (Fig. 1a). The arthritic index
represents the grade of arthritis that was used to assess
the efficacy of MAG-ω3 compounds. In the CFA group,
diseased rats without any treatment showed an increased
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(Fig. 1b). Compared with CFA group, administration of
MAG-DHA did not significantly reduce arthritis score
(Fig. 1b). However, MAG-EPA and MAG-DPA were ob-
served to have significant activity in preventing the
progression of arthritic disease with the arthritis score
significantly lowered in treated CFA rats from day 16 to
22 (Fig. 1b).
Moreover, as illustrated in Fig. 1c, macroscopic images
revealed that MAG-EPA-treatment decreased arthritic
symptoms when compared to those observed in the un-
treated CFA group. Histological analysis of joints in CFA
rats demonstrated an extensive proliferation of synovial
cells, resulting in pannus formation and infiltration of
leukocytes to the sub synovial region, with damage to ar-
ticular surfaces and discontinuity in the cartilage when
compared to histological joint sections obtained from
control rats (Fig. 1d-e). However, CFA rats treated with
MAG-EPA showed a reduced level of severe arthritic
and degenerative changes when compared to the mor-
phological changes observed in the untreated CFA group
(Fig. 1f ).Fig. 2 Effects of MAG- ω3 treatments on pro-inflammatory cytokine levels. (a
of control, complete Freund’s adjuvant (CFA)-treated, CFA + eicosapentaenoic
monoglyceride (MAG-DHA)-treated and CFA + -docosapentaenoic acid mono
Methods section (n = 6, *P ≤0.05)Effects of MAG-ω3 on pro-inflammatory cytokine levels
To investigate possible mechanisms by which MAG-ω3
compounds decrease arthritis progression, levels of key
pro-inflammatory cytokines including IL-17A, IL-1β, IL-
6 and TNFα were measured by specific ELISA on day 22
in plasma derived from control, CFA, CFA + MAG-DHA-,
CFA + MAG-EPA- and CFA + MAG-DPA-treated rats. As
illustrated in Fig. 2, IL-17A, IL-1β, IL-6 and TNFα levels
were significantly higher in the plasma of CFA rats when
compared to plasma levels in control animals. In contrast,
the levels of these cytokines were significantly lower in
the plasma of MAG-EPA- and MAG-DPA-treated ani-
mals when compared to untreated CFA rats. Of note,
circulating levels of IL-17A, IL-1β, IL-6 and TNFα were
less reduced in the presence of MAG-DHA than in
MAG-EPA- and MAG-DPA-treated animals.
Effect of MAG-ω3 on NFκB pathway activation
P38 MAPK and NFκB pathways are known to contribute
to the overexpression of pro-inflammatory cytokines,
chemokines, MMPs and signaling enzymes such as
COX-2 in the inflamed synovium. In order to determine) IL-17A, (b) IL-1β, (c) IL-6 and (d) TNFα levels were assessed in plasma
acid monoglyceride (MAG-EPA)-treated, CFA + docosahexaenoic acid
glyceride (MAG-DPA)-treated rats using specific ELISA as described in the
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compounds are mediated by these specific pathways, the
activation of p38MAPK and NFκB was investigated by
western blot in paw homogenates derived from control
and CFA rats, either untreated or treated with MAG-
EPA, MAG-DPA or MAG-DHA. Western blot analysisFig. 3 Effect of MAG-ω3 on activation of p38 mitogen-activated protein kin
analysis of hind paw homogenates derived from control complete Freund’
(MAG-EPA), CFA + docosapentaenoic acid monoglyceride (MAG-DPA) and
using specific antibodies against the phosphorylated form of p38MAPK (P-p38
homogenates are expressed as a function of p38 MAPK signals (n = 6, *P <0.0
total form of p65 NFκB in control, untreated CFA and CFA + MAG-ω3- treated
of total p65 NFκB (n = 6, *P <0.05). c Western blot and quantitative analyses o
from control and the four series of CFA-treated rats. Staining densities in homrevealed that MAG-EPA, MAG-DPA and MAG-DHA
treatments all decreased CFA-induced phosphorylation
of p38 MAPK to a similar extent compared to untreated
CFA animals (Fig. 3a). Western blot and quantitative
immunoblot analyses were also performed on hind paw
homogenates derived from untreated control andase (MAPK) and NFκB pathways. a Western blot and quantitative
s adjuvant (CFA), CFA + eicosapentaenoic acid monoglyceride
CFA + docosahexaenoic acid monoglyceride (MAG-DHA)-treated rats
MAPK) and total form of p38MAPK. Staining densities of P-p38MAPK in
5). b Western blot analysis of the phosphorylated form of p65 NFκB and
rats. Staining densities in paw homogenates are expressed as a function
f TNFα, cyclooxygenase (COX)-2, and β-actin protein detection derived
ogenates are expressed as a function of β-actin signals. (n = 6, *P <0.05)
Fig. 4 Effects of MAG-ω3 on metalloproteinase expression in paw
tissues. a Western blot analysis of hind paw homogenates derived
from control, complete Freund’s adjuvant (CFA), CFA + eicosapentaenoic
acid monoglyceride (MAG-EPA)-, CFA + docosapentaenoic acid
monoglyceride (MAG-DPA)-, and CFA + docosahexaenoic acid
monoglyceride (MAG-DHA) -treated rats, using specific antibodies
against matrix metalloproteinase (MMP)-2, MMP-9 and β-actin.
b Quantitative analysis of MMP-2/β-actin and c MMP-9/β-actin density
ratios as a function of experimental conditions (n = 6, *P <0.05)
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total and phosphorylated forms of p65 NFκB. Results re-
vealed that MAG-EPA and MAG-DPA treatments de-
creased p65 NFκB phosphorylation levels in paw tissues
compared to that observed in untreated CFA rats (Fig. 3b),
with significant reductions of 81 ± 3.1 % and 76 ± 2.7 %,
respectively, following comparative analysis of P-NFκB/
NFκB ratios after normalization of identical immuno-
blot membrane areas (Fig. 5b). However, no signifi-
cant difference in p65 NFκB phosphorylation levels in
CFA + MAG-DHA-treated rats was observed when com-
pared to untreated CFA animals (Fig. 3b).
We assessed the expression of TNFα and COX-2 in
tissue homogenates derived from control as well as un-
treated and MAG-ω3-treated CFA rats. Results revealed
a significant increase in TNFα and COX-2 protein expres-
sion in CFA rats when compared to expression levels in
control animals. Treatment with MAG-EPA and MAG-
DPA, however, reduced TNFα and COX-2 expression
levels compared to untreated CFA animals (Fig. 3c, top
panel). Following quantitative analysis of identical immu-
noblot membrane areas normalized as a function of total
β-actin staining in corresponding fractions, MAG-EPA
and MAG-DPA treatment significantly reduced TNFα
and COX-2/β-actin staining density ratios when compared
to the ratios quantified in untreated CFA rats (Fig. 3c,
lower panels).
Effect of MAG-ω3 treatment on metalloproteinase
expression
Further experiments were performed to assess the effect
of MAG-DHA, MAG-EPA and MAG-DPA treatments on
MMP-2 and MMP-9 expression levels as these proteins
have been shown to be involved in the degradation of joint
cartilage. Western blot analyses were performed on hind
paw and knee cartilage homogenates derived from control,
CFA, CFA + MAG-DHA-, CFA + MAG-EPA- and CFA +
MAG-DPA-treated rats (Fig. 4). Analysis revealed in-
creased MMP-2 and MMP-9 expression levels in cartil-
age homogenates derived from CFA rats comparatively
to controls. However, a reduced staining of MMP-2 and
MMP-9 proteins expression was obtained following
treatments with MAG-DHA, MAG-EPA and MAG-
DPA compounds in CFA rats (Fig. 4a-c). β-actin staining
remained constant from one preparation to the other
(Fig. 4a).
Effect of vitamin E on MAG-EPA-mediated anti-
inflammatory properties
Additional experiments were performed to determine
whether vitamin E (commonly used as an antioxidant in
omega-3 formulations) exerts synergistic or antagonistic
effects on anti-inflammatory properties of MAG-EPA in
CFA animals. Combined treatment of vitamin E (53 mg/
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15 days following CFA injection after which its effects on
hind paw thickness, COX-2 expression levels and pro-
inflammatory cytokine profiles were investigated. Figure 5a
demonstrates that combined treatment of MAG-EPA andFig. 5 Effect of vitamin E treatment on eicosapentaenoic acid monoglycer
adjuvant (CFA) rats. a Hind paw thickness (mm) as a function of time (days
absence and presence of vitamin E (vit E). Results represent the mean ± sta
and subsequent quantitative analysis of paw homogenate fractions derived
treated rats using specific antibodies against cyclooxygenase (COX)-2 and β
of β-actin signals. (n = 6, *P <0.05). c Determination levels of IL-17A, IL-6, IL-1β
in the absence and presence of vitamin E, (n = 6, *P ≤0.05)vitamin E in CFA rats incurred an increase in hind paw
thickness similar to that of CFA-untreated animals. How-
ever, treatments with MAG-EPA alone significantly re-
duced hind paw thickness when compared to untreated
CFA rats. The effect of combined MAG-EPA and vitaminide (MAG-EPA)-induced anti-inflammatory effects in complete Freund’s
) was measured in control, CFA, CFA + MAG-EPA-treated rats in the
ndard error of the mean (n = 6 per group). b Typical western blots
from control, CFA, CFA + MAG-EPA + vitamin E- and CFA+ MAG-EPA-
-actin. Staining densities in homogenates are expressed as a function
and TNFα in plasma of control, CFA-treated, CFA + MAG-EPA-treated rats
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by western blot in the different preparations of hind paw
homogenates. Figure 5b shows that combined treatment of
MAG-EPA and vitamin E inhibited the reduction in COX2
protein expression level observed in CFA + MAG-EPA
treated animals. Lastly, the levels of the pro-inflammatory
cytokines IL-17A, IL-1β, IL-6 and TNFα were determined
in plasma derived from control, CFA- and CFA + MAG-
EPA-treated rats in the absence and presence of vitamin E
(Fig. 5c). Data demonstrate that combined MAG-EPA and
vitamin E treatment also curtailed the effect induced by
MAG-EPA on pro-inflammatory cytokine levels in CFA
rats (Fig. 5c). Moreover, no significant difference was ob-
served between CFA + MAG-EPA + vitamin E-treated and
CFA-untreated rats (Fig. 5c). Taken together, these results
indicate that vitamin E displays antagonistic effects on
MAG-EPA anti-inflammatory properties in our rat model
of RA.
Discussion
The present study shows an anti-inflammatory effect of
MAG-ω3 compounds in a rat model of CFA-induced
arthritis. The ability of ω3 fatty acids to downregulate
several aspects of inflammation suggests that these fatty
acids may be important in determining the development
and severity of inflammatory diseases and that they may
be useful as a component of therapy. Particular interest
in the therapeutic potential of ω3 fatty acids in RA was
shown quite early on, because of the recognition that
these fatty acids target arachidonic acid metabolism
known to be involved in this disease. In the present study,
we used a CFA model of RA to assess the effects of MAG-
EPA, MAG-DPA and MAG-DHA treatment on disease
progression and severity. MAG-EPA treatment (human
equivalent of 3g/day) during 7 days was found to decrease
paw swelling, pro-inflammatory marker levels (IL-17A,
IL-6, IL-1β, TNFα, COX-2 and MMPs) as well as disease
severity. We propose that MAG-EPA is able to reduce
arthritis severity in a CFA rat model.
Anti-inflammatory effects of MAG-ω3 compounds on
arthritis severity
Clinical reports have shown that intake of ω3 PUFAs is
associated with a reduction in the severity of RA [3, 26].
In the majority of these studies however, a heterogeneous
mixture of the two main active ω3 PUFAs was used: EPA
and DHA [26, 34]. Many studies have also reported differ-
ential effects of EPA, DHA and their metabolites both in a
clinical setting and at the laboratory bench.
There are multiple factors that contribute to the differ-
ential effects of EPA and DHA, including differences in
direct and indirect activation of transcription factors, im-
pact of length, degree of saturation and stability of fatty
acids on their efficacy, and differential efficiency forincorporation of the fatty acids into phospholipids [35].
Potency of the metabolites of EPA and DHA are often
markedly different to the parent long-chain ω3 PUFA, and
divergence in the effectiveness of enzymes to metabolize
EPA and DHA can contribute to the observed diversity in
cellular response [35]. A preclinical study demonstrated
that both EPA and DHA suppressed streptococcal cell
wall-induced arthritis in rats, with EPA being the more ef-
fective of the two fatty acids [36]. However, a second study
showed rats fed an EPA-enriched diet had an increased in-
cidence of arthritis in a collagen-induced arthritis (CIA)
model [37]. Olson et al. demonstrated that dietary supple-
mentation with DHA, but not with fish oil or DHA/EPA,
significantly reduced arthritis severity, anti-collagen anti-
body production and inflammation associated with CIA in
mice [38]. A recent study by Torres-Guzman et al. has
shown an antinociceptive and anti-inflammatory effect of
DHA following repeated systemic or intra-articular treat-
ment in a mouse model of chronic CFA-induced knee
arthritis [39]. To our knowledge, the biochemical effects
of ω3 DPA have not been extensively studied in preclinical
models due to the limited availability and high cost of
pure compound.
In the present study, we assessed the ability of MAG-
EPA, MAG-DHA and MAG-DPA to resolve inflamma-
tion in an in vivo model of RA induced by CFA. Fatty
acids in monoglyceride form confer increased bioavail-
ability of ω3 and are generally recognized as safe and are
widely used as emulsifying agent in the food industry. In
a previous study, we have demonstrated that DHA
monoacylglyceride increased the systemic bioavailability
of DHA compared to commercially available marine oil
[30–32]. Omega-3 monoglycerides have better solubility
in physiological solution and pharmacokinetics than
omega-3 methyl ester or ethyl ester (EE) and more stable
than omega-3 free fatty acid. Preclinical and clinical stud-
ies showed that the intestinal absorption of DHA and EPA
given as EE was lower than seen in the case of triglyceride
(TG) or free acid [40, 41]. Moreover, Dyerberg et al. and
Cruz-Hernendez et al. have shown that EPA in the form
of monoacylglyceride alone or in re-esterified TGs in-
creases the oral bioavailability of EPA compared to natural
TG form made from fish oil [40, 42]. Moreover, Banno et
al. demonstrated that DHA monoglycerides and diglycer-
ide are absorbed and transported more effectively than
DHA-TG and EE in rats under a water-restricted condi-
tion [43]. In a preclinical model, Cruz-Hernandez et al.
have shown that malabsorption due to enzyme insuffi-
ciency may lead to decreased circulating and tissue levels
of EPA and such a deficiency can be reversed using MAG
provided as sn-1(3)-MAG or protected sn-2-MAG [42].
Hence, Philippoussi et al. demonstrated that lipids in
monoglyceride form display better induction of apoptosis
in T-cells when compared with corresponding free fatty
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MAG-ω3 might be favorable in terms of absorption and
utilization efficiency. Herein, our data revealed that MAG-
EPA and MAG-DPA treatments were more effective than
MAG-DHA in resolving inflammation and reducing
arthritis severity in our preclinical model of RA. Histo-
pathological analysis also correlated with the reduction
in clinical scores, showing an overall reduction in both
inflammation and bone and cartilage destruction in joints
of animals treated with MAG-EPA or MAG-DPA.
Current literature indicates that supplemental ω3 PUFA
decreases inflammatory cytokines [16] and eicosanoids
[17, 38] in patients with RA. As a result, these effects
should reduce pain and cartilage destruction which, in
turn, may lead patients to decrease their use of pain-
controlling drugs. Randomized controlled trials of ω3 fatty
acids (at doses between 1 and 7g per day) in RA have
reported improvements in several clinical outcomes in-
cluding reduced duration of morning stiffness, reduced
number of tender or swollen joints, reduced joint pain, re-
duced time to fatigue, increased grip strength and de-
creased use of pain-controlling drugs [3, 18, 45]. In a
recent meta-analysis encompassing data from 17 trials on
ω3 fatty acids and pain [26], fish oil was found to reduce
patient-assessed joint pain, duration of morning stiffness,
number of tender joints and use of pain-controlling drugs.
It is therefore of key clinical interest to find an easy-to-use,
well-absorbed ω3 PUFA that exerts a pro-resolving effect
and consequently with the ability to reduce arthritis sever-
ity and progression.
Possible mechanisms underlying the anti-inflammatory
effect of MAG-EPA and MAG-DPA in the current CFA
model of arthritis
Although several studies have demonstrated anti-
inflammatory effects of ω3 PUFA [3, 18], less is known
as to the molecular mechanisms underlying these effects.
One possible explanation, based on current literature, is
that both direct and indirect effects may explain the bio-
logical actions of ω3 PUFA. Direct effects may include
competition of DHA, EPA or DPA with arachidonic acid
as a substrate for COX and LOX, thus reducing the pro-
duction of inflammatory eicosanoids [3, 46–48]. More-
over, we and others have recently demonstrated that the
anti-inflammatory actions of ω3 PUFA and MAG-ω3
compounds may partially be explained by inhibition of
NFκB-mediated COX-2 induction and activity [11, 49].
Expression of both COX-1 and COX-2 is increased in
the synovium of patients with RA [11]; in addition, syn-
ovial fluid contains high levels of pro-inflammatory eicosa-
noid products from both the COX and LOX pathways
[11] as well as high levels of pro-inflammatory cytokines
including TNF, IL-1β, IL-17A, IL-6, IL-8 and GMCFS
[50]. In this study, we demonstrate that MAG-EPAtreatment is able to reduce the NFκB and p38 MAPK
activation pathways, resulting in decreased levels of
pro-inflammatory mediators such as COX-2, IL-17A,
TNFα, IL-6, IL-1β, MMP-2 and MMP-9.
Indirect effects may also contribute to the biological
actions of ω3 PUFA, including the participation of Rvs
and protectins, which are lipid mediators enzymatically
synthesized in vivo from EPA, DPA or DHA and shown
to promote the resolution of inflammation with greater
potency than their parent precursors [14, 51]. To date,
there are only limited data investigating the actions of
Rvs in animal models of arthritis. Accordingly, protective
effects of aspirin-triggered-RvD1 (AT-RvD1) were ob-
served following an intraplantar injection of CFA as a
model of inflammatory arthritic pain [52]. In this latter
study, AT-RvD1 (100 ng intraperitoneally twice daily)
was shown to have antihyperalgesic effects, reducing
hind paw withdrawal frequency, which was associated
with decreased TNFα and IL-1β within the paw [52].
Moreover, several Rvs including RvD1, RvD2 and RvE1
have recently been identified as potent analgesics for treat-
ing inflammatory pain, acting as potent endogenous inhibi-
tors that differentially regulate transient receptor potential
subtype V1 (TRPV1) and A1 (TRPA1) agonist-elicited
acute pain [14, 51].
RA is also known to be directly associated with an in-
crease in ω-6 and a reduction in ω-3 fatty acid levels in
blood circulation and tissues [3]. Previous studies from
our group have shown that MAG-ω3 treatment increases
the level of ω3 PUFA in plasma, red blood cells and tissues,
suggesting a high ω3 PUFA bioavailability and thereby
likely contributing to reducing inflammation [30–32]. We
also established that MAG-ω3 compounds were metabo-
lized by lipoxygenases and CYP450 to generate metabolites
mediating anti-inflammatory effects in our experimental
models [30–32]. We propose that MAG-EPA not only im-
proves the plasma and cell/tissue content of EPA but also
increases the production of beneficial metabolites such as
Rvs [14] and exerts pro-resolving actions in our model of
RA. Accordingly, elevated levels of 5-LO and 15-LO (key
enzymes involved in Rv and lipoxin biosynthesis) have also
been detected in RA synovium [53, 54]. A study using
mass spectrometry-based lipidomic analyses has identified
RvD5 and Maresin 1(MaR1) within the synovial fluid from
RA patients [55]. Such findings warrant further study, such
as stratifying patients according to disease severity, and
taking into account differences in therapeutic and dietary
intervention with ω3 supplementation.
Hypotheses would suggest that vitamin E and ω3
PUFAs have synergistic anti-inflammatory effects [56].
However, vitamin E is a potent antioxidant interrupting
lipid peroxidation that has been purported to have an-
tagonistic effects to ω3 PUFA, in particular in carcino-
genesis [57]. Our results corroborate the hypothesis of a
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take on inflammatory biomarkers. PUFAs are able to
auto-oxidize such that their incorporation has been found
to induce lipid peroxidation and apoptosis in vitro and in
animal models of cancer [58, 59]. In these latter studies,
ω3 PUFAs led to tumor growth suppression while adding
vitamin E to ω3 PUFAs abolished this effect [58, 59], sug-
gesting that ω3 PUFA-induced lipid peroxidation is likely
not toxic per se but rather acts as a tumor cell growth and
apoptosis regulator [60]. Moreover, in lung cells, antioxi-
dants have been demonstrated to increase tumor cell prolif-
eration in vitro and in vivo by reducing p53 activation [61].
Experimental studies and large clinical trials quite convin-
cingly suggest that antioxidants, including isoflavones, caro-
tenes and vitamins, should not be recommended for the
prevention of lung cancer and that their use may promote
tumor growth [62–64]. Moreover, an epidemiological study
by Julia et al. demonstrated an inverse relationship between
PUFA intake and elevated levels of CRP in individuals tak-
ing vitamin E supplements [65]. Such interaction between
PUFAs and vitamin E intake in inflammation will clearly
necessitate further investigation in preclinical models of RA
and human studies.Conclusion
The present findings demonstrate that MAG-EPA, with-
out vitamin E, exerts anti-inflammatory properties in a
CFA animal model of arthritis. Furthermore, when ad-
ministrated per os, MAG-EPA represents a stable com-
pound which could serve as a precursor to generate a
variety of PUFA-derived mediators such as Rvs known
to directly mediate anti-inflammatory and pro-resolving
effects through specific receptors. Consequently MAG-
EPA formulations without vitamin E could provide a
new and interesting approach for the management of
rheumatoid arthritis diseases.
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